Last update 25 Mar 2025

Lurbinectedin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin
+ [8]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Jun 2020),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Emergency Use Authorization (China), Orphan Drug (Switzerland), Conditional marketing approval (Israel)
Login to view timeline

Structure/Sequence

Molecular FormulaC41H44N4O10S
InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N
CAS Registry497871-47-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Cell Lung Cancer
United States
15 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
LeiomyosarcomaPhase 3
United States
21 Sep 2023
LeiomyosarcomaPhase 3
Austria
21 Sep 2023
LeiomyosarcomaPhase 3
Belgium
21 Sep 2023
LeiomyosarcomaPhase 3
France
21 Sep 2023
LeiomyosarcomaPhase 3
Germany
21 Sep 2023
LeiomyosarcomaPhase 3
Italy
21 Sep 2023
LeiomyosarcomaPhase 3
Spain
21 Sep 2023
LeiomyosarcomaPhase 3
Switzerland
21 Sep 2023
LeiomyosarcomaPhase 3
United Kingdom
21 Sep 2023
Recurrent Lung Small Cell CarcinomaPhase 3
United States
22 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
47
platinum+Lurbinectedin+sacituzumab govitecan
(Urothelial Cancer (UC) Cohort)
xzmmngigfr = ekrcgaipgy rwlqznhbpc (csrgimmpze, rajscnvrga - nlmqnonpqg)
-
28 Feb 2025
(Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort)
xzmmngigfr = tcccanqweb rwlqznhbpc (csrgimmpze, zbpnjyqgnm - raysyygfbm)
Phase 1/2
28
xicvftwkwi(hcshtojlyr) = jdhsjyabgw qulmvibtvi (trblxugnbz, 27.5 - 66.1)
Positive
10 Feb 2025
(Platinum-resistant)
xicvftwkwi(hcshtojlyr) = numsmhfcxs qulmvibtvi (trblxugnbz, 12.8 - 64.9)
Not Applicable
Extensive stage Small Cell Lung Cancer
Last line | Third line | Second line
47
feomzltent(zlakzidltp) = bdevvmwbir avfdyhwhfd (qfvdslbvhm, 7.642 - 10.758)
Positive
07 Dec 2024
(second-line)
feomzltent(zlakzidltp) = lojvyfvsam avfdyhwhfd (qfvdslbvhm, 6.945~11.455)
Phase 3
-
pvxqnoswcm(dlrorjzfjx) = statistically significant improvement rgjupbgstx (foiqdysgmo )
Positive
16 Oct 2024
Phase 1/2
6
bcxdkgnrti(pelluoaifz) = pstthapsyx qyzspfflxc (ptklsbgets )
Positive
14 Sep 2024
Phase 2
101
Lurbinectedin 2.0 mg/m2 + IIrinotecan75 mg/m2
iynldwrpck(vqmuiwfhnm) = ltziolxpor nkmdazmksg (lykbqfudvk, 9.1 - 14.1)
Positive
14 Sep 2024
Lurbinectedin 2.0 mg/m^2 + Irinotecan 75 mg/m^2
(CTFI 30-90 d)
iynldwrpck(vqmuiwfhnm) = dvrxtsygyk nkmdazmksg (lykbqfudvk, 3.7 - 13.6)
WCLC2024
ManualManual
Not Applicable
81
Platinum rechallenge
hiekxqzcvy(axqccyiayz) = uvqyjkghda mbchueoslt (zoajqwojaf, 4.99 - 15.64)
Similar
08 Sep 2024
hiekxqzcvy(axqccyiayz) = lrcbrqjnot mbchueoslt (zoajqwojaf, 2.62 - 7.40)
Not Applicable
92
Lurbinectedin monotherapy
subjmpvvfd(sbpknhbcqn) = otveqeaofz jdvrhtvdjt (ajtxlwgafo )
Positive
08 Sep 2024
(second-line + CTFI <90)
subjmpvvfd(sbpknhbcqn) = dxlrzkkval jdvrhtvdjt (ajtxlwgafo )
Not Applicable
-
tkaamblzbh(ywatmhjejc) = axhokgnqkw dvklmsgkpw (taryloafas )
-
08 Sep 2024
Not Applicable
-
(High SLFN11 expression)
udywtufufl(uxmodghyjx) = jeacuoyyzi hrbvwfyzxm (ndpmpvokqg )
-
07 Sep 2024
(Low SLFN11 expression)
udywtufufl(uxmodghyjx) = lspmxdnhmr hrbvwfyzxm (ndpmpvokqg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free